October 4, 2017 — MyoKardia Inc. recently provided a clinical update on its MYK-491 program for dilated cardiomyopathy.
...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
October 04, 2017
September 19, 2017 — The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain ...
September 19, 2017September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in ...
September 12, 2017
September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressively ...
September 12, 2017
September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk by ...
September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with ...
September 12, 2017
September 11, 2017 — Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the ...
September 11, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc. announced results from an analysis of real-world data ...
August 28, 2017
August 18, 2017 — Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual ...
August 18, 2017
August 3, 2017 — Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short ...
August 03, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are ...
July 25, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet therapy ...
July 12, 2017
July 7, 2017 — Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a ...
July 07, 2017
July 5, 2017 — Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of ...
July 05, 2017
June 29, 2017 — Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for ...
June 29, 2017